AASLD巅峰访谈丨Nguyen教授：乙型肝炎的诊疗新进展，能否实现治愈？ 2017-11-29

[APASL我在现场]陈国凤教授：中国慢性丙型肝炎基因1b型患者由PEG/RBV向DAA转换的临床探索 2016-02-23

[APASL2014]III期随机、双盲研究评估Simeprevir与Telaprevir分别结合PEG-IFN/RBV治疗经治基因1型慢性丙型肝炎患者的有效性、安全性和耐受性：ATTAIN研究 2014-04-02

[APASL2014]Individualizing PEG-IFN and RBV Doses in HCV Genotype 2 2014-03-14

[APASL2014]Lipid-Lowering in NASH 2014-03-14

[APASL2014]Updates on Prevention of Mother-To-Child Transmission 2014-03-13

[APASL2014]Using pre-S2 Antigen to Predict Treatment Response 2014-03-13

[APASL2014]应用前-S2抗原预测疗效 2014-03-13

[YAHN2013]肠外营养治疗——肝功能障碍与治疗 2013-08-17

[DICID2012]决定乙型肝炎患者治疗开始和终止的因素——Nancy W.Y. Leung教授访谈 2012-07-20

[ISVHLD2012]治愈乙型肝炎有必要吗？有可能吗？——Prof.Timothy M. Block专访 2012-06-28

[PHC2012]Boceprevir和Telaprevir联合PEG-IFN/RBV治疗应答预测因素——Prof.Paul Y.Kwo专访 2012-03-13

[AASLD2011]直接作用的抗病毒药物(DAA) ：如何起效及其局限性——Prof.Raymond Chung访谈 2011-11-18

[AASLD2011]全球疫苗公平和乙肝疫苗接种现状——Jaime Sepulveda， MD访谈 2011-11-10

[APASL2011]Eating yourself to survival 2011-02-25

[APASL2011]Management of anemia in HCV patients: Timing is everything 2011-02-23

[APASL2011]Immunomodulatory Action of Interferons and Nucleoside/nucleotide Analogues: They Are Different 2011-02-23

[APASL2011]The Role of Immune Control in Curing Patients with Chronic Hepatitis B-Interview with Harry Janssen 2011-02-17

[APASL2011]实现免疫控制是病毒性肝炎治愈的根本——荷兰鹿特丹Erasmus大学Harry L.A. Janssen教授访谈 2011-02-17

范上达教授专访 2010-06-24